172 related articles for article (PubMed ID: 33927186)
1. Sensitive multiple myeloma disease monitoring by mass spectrometry.
Santockyte R; Jin C; Pratt J; Ammar R; Desai K; Bolisetty M; Das P; Popa-McKiver M; Puig O
Blood Cancer J; 2021 Apr; 11(4):78. PubMed ID: 33927186
[No Abstract] [Full Text] [Related]
2. Commentary.
Bennett ST
Clin Chem; 2010 Sep; 56(9):1393. PubMed ID: 20802100
[No Abstract] [Full Text] [Related]
3. Comparison of mass spectrometry and flow cytometry in measuring minimal residual disease in multiple myeloma.
Foureau D; Bhutani M; Guo F; Rigby K; Leonidas M; Tjaden E; Fox A; Atrash S; Paul B; Voorhees PM; Usmani SZ
Cancer Med; 2021 Oct; 10(20):6933-6936. PubMed ID: 34494717
[TBL] [Abstract][Full Text] [Related]
4. Free light chain testing in follow-up of multiple myeloma.
Van Gysel M; Mariën G; Verhoef G; Delforge M; Bossuyt X
Clin Chem Lab Med; 2006; 44(8):1044-6. PubMed ID: 16879076
[No Abstract] [Full Text] [Related]
5. Sensitivity of serum free light chain measurement of residual disease in multiple myeloma patients.
Mead GP; Drayson MT
Blood; 2009 Aug; 114(8):1717. PubMed ID: 19696211
[No Abstract] [Full Text] [Related]
6. Evaluation of the heavy/light-chain assay for the diagnosis and monitoring of multiple myeloma.
Chae H; Cha K; Kim M; Kim Y; Min CK
Int J Lab Hematol; 2013 Oct; 35(5):e10-2. PubMed ID: 23311353
[No Abstract] [Full Text] [Related]
7. Benefits of new immunoglobulin-derived biomarkers for the diagnosis and follow-up of patients with dysglobulinemia.
Ermak N; Nguyen-Khoa T; Alyanakian MA
Ann Biol Clin (Paris); 2016 Oct; 74(5):597-605. PubMed ID: 27707674
[TBL] [Abstract][Full Text] [Related]
8. Incidence and clinical characteristics of multiple myeloma with low M-protein levels and normal values of hemoglobin, creatinine, calcium, and serum free light chain ratio.
Szabo AG; Klausen TW; Abildgaard N; Gregersen H; Silkjær T; Pedersen PT; Pedersen RS; Helleberg C; Hermansen E; Schnack BI; Vangsted AJ
Blood Cancer J; 2021 Apr; 11(4):70. PubMed ID: 33828079
[No Abstract] [Full Text] [Related]
9. Immunoglobulin heavy and light chain isotypes in multiple myeloma patients.
Ansari NA; Owais M; Usha
Asian Pac J Cancer Prev; 2007; 8(4):593-6. PubMed ID: 18260735
[TBL] [Abstract][Full Text] [Related]
10. Prevalence and monitoring of oligosecretory myeloma.
Larson D; Kyle RA; Rajkumar SV
N Engl J Med; 2012 Aug; 367(6):580-1. PubMed ID: 22873553
[No Abstract] [Full Text] [Related]
11. Diagnostic thresholds for free light chains in multiple myeloma depend on the assay used.
Bossuyt X; Delforge M; Reynders M; Dillaerts D; Sprangers B; Fostier K; Poesen K; Vercammen M
Leukemia; 2018 Aug; 32(8):1815-1818. PubMed ID: 29674643
[No Abstract] [Full Text] [Related]
12. Role of serum free light chain assay in the detection of early relapse and prediction of prognosis after relapse in multiple myeloma patients treated upfront with novel agents.
Tacchetti P; Pezzi A; Zamagni E; Pantani L; Rocchi S; Zannetti BA; Mancuso K; Rizzello I; Cavo M
Haematologica; 2017 Mar; 102(3):e104-e107. PubMed ID: 27909220
[No Abstract] [Full Text] [Related]
13. Involved/uninvolved heavy/light chain index can predict progression in transplanted multiple myeloma patients.
Espiño M; Arteche-López A; Medina S; Muñoz-Calleja C; Blanchard MJ; Alegre A; López-Jiménez FJ; Villar LM
Bone Marrow Transplant; 2017 Aug; 52(8):1206-1207. PubMed ID: 28581457
[No Abstract] [Full Text] [Related]
14. [A simple procedure for the reliable determination of free L-chains in the serum].
Malberg K; Elendt D; Petermann B; Wutke K
Folia Haematol Int Mag Klin Morphol Blutforsch; 1981; 108(4):553-8. PubMed ID: 6170549
[TBL] [Abstract][Full Text] [Related]
15. Reduction of serum free light chains predict renal recovery.
Hutchison CA
Ann Hematol; 2010 Jun; 89(6):627-8. PubMed ID: 19784650
[No Abstract] [Full Text] [Related]
16. Levels of uninvolved immunoglobulins predict clinical status and progression-free survival for multiple myeloma patients.
Harutyunyan NM; Vardanyan S; Ghermezi M; Gottlieb J; Berenson A; Andreu-Vieyra C; Berenson JR
Br J Haematol; 2016 Jul; 174(1):81-7. PubMed ID: 27017948
[TBL] [Abstract][Full Text] [Related]
17. [Clinical value of the blood measurement of the free light chains of immunoglobulins].
Bidet A; Marit G; Bérard AM
Ann Biol Clin (Paris); 2008; 66(4):427-31. PubMed ID: 18725344
[TBL] [Abstract][Full Text] [Related]
18. Detecting only light chains, now what?
Jacobs JF; Joosten I; Klasen IS
Clin Chem; 2010 Aug; 56(8):1368. PubMed ID: 20668174
[No Abstract] [Full Text] [Related]
19. Disclosure of hidden free light chains by immunosubtraction.
Thelen MH; van Bezu J; Kok A; Schutgens RB
Clin Chem; 2002 Nov; 48(11):2044-5. PubMed ID: 12406991
[No Abstract] [Full Text] [Related]
20. Quantification by Ultrafiltration and Immunofixation Electrophoresis Testing for Monoclonal Serum Free Light Chains.
Singh G; Bollag R
Lab Med; 2020 Nov; 51(6):592-600. PubMed ID: 32285117
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
